AU2019223168B2 - EGFR dimer disruptors and use of the same - Google Patents

EGFR dimer disruptors and use of the same Download PDF

Info

Publication number
AU2019223168B2
AU2019223168B2 AU2019223168A AU2019223168A AU2019223168B2 AU 2019223168 B2 AU2019223168 B2 AU 2019223168B2 AU 2019223168 A AU2019223168 A AU 2019223168A AU 2019223168 A AU2019223168 A AU 2019223168A AU 2019223168 B2 AU2019223168 B2 AU 2019223168B2
Authority
AU
Australia
Prior art keywords
egfr
compound
equiv
dgd1202
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019223168A
Other languages
English (en)
Other versions
AU2019223168A1 (en
Inventor
Theodore S. Lawrence
Mukesh K. Nyati
Jason Christopher Rech
Brennan Taylor WATCH
Christopher Whitehead
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan (System)
Original Assignee
University of Michigan (System)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan (System) filed Critical University of Michigan (System)
Publication of AU2019223168A1 publication Critical patent/AU2019223168A1/en
Application granted granted Critical
Publication of AU2019223168B2 publication Critical patent/AU2019223168B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019223168A 2018-02-23 2019-02-25 EGFR dimer disruptors and use of the same Active AU2019223168B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862634452P 2018-02-23 2018-02-23
US62/634,452 2018-02-23
PCT/US2019/019391 WO2019165358A1 (en) 2018-02-23 2019-02-25 Egfr dimer disruptors and use of the same

Publications (2)

Publication Number Publication Date
AU2019223168A1 AU2019223168A1 (en) 2020-09-10
AU2019223168B2 true AU2019223168B2 (en) 2024-09-12

Family

ID=67688515

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019223168A Active AU2019223168B2 (en) 2018-02-23 2019-02-25 EGFR dimer disruptors and use of the same

Country Status (11)

Country Link
US (2) US11358965B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755323A4 (cg-RX-API-DMAC7.html)
JP (2) JP7497046B2 (cg-RX-API-DMAC7.html)
KR (1) KR102748047B1 (cg-RX-API-DMAC7.html)
CN (1) CN111886009A (cg-RX-API-DMAC7.html)
AU (1) AU2019223168B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020017184A2 (cg-RX-API-DMAC7.html)
CA (1) CA3091834A1 (cg-RX-API-DMAC7.html)
EA (1) EA202092000A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020008767A (cg-RX-API-DMAC7.html)
WO (1) WO2019165358A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019223168B2 (en) 2018-02-23 2024-09-12 The Regents Of The University Of Michigan EGFR dimer disruptors and use of the same
CN119454706A (zh) * 2019-08-22 2025-02-18 密歇根大学董事会 治疗kras相关癌症的方法
IL296091A (en) * 2020-03-05 2022-11-01 Univ Michigan Regents Inhibitors of braf, kras, egfr and other targets and their uses
CN115397413A (zh) * 2020-03-05 2022-11-25 密歇根大学董事会 Egfr、kras、braf和其他靶标的抑制剂及其用途
MX2023003362A (es) 2020-09-23 2023-05-30 Scorpion Therapeutics Inc Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer.
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
TW202229282A (zh) 2020-09-30 2022-08-01 美商史考皮恩治療有限公司 治療癌症之方法
WO2022072632A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
BR112023006531A2 (pt) 2020-10-09 2023-10-03 Scorpion Therapeutics Inc Inibidores heterocílicos de egfr e/ou her2, para uso no tratamento de câncer
WO2022077154A1 (en) * 2020-10-12 2022-04-21 The Regents Of The University Of Michigan Synthesis of egfr modulators
CN116997551A (zh) * 2020-10-12 2023-11-03 密歇根大学董事会 Egfr调节剂的合成
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
KR20240016250A (ko) * 2021-04-02 2024-02-06 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료를 위한 병용요법
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
WO2024254298A1 (en) 2023-06-08 2024-12-12 Scorpion Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
EP4724150A1 (en) 2023-06-08 2026-04-15 Antares Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547977A (en) 1967-10-27 1970-12-15 Velsicol Chemical Corp Novel carbanilates
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US9029502B2 (en) 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
WO2014176475A2 (en) * 2013-04-26 2014-10-30 The Regents Of The University Of Michigan Egfr inhibitors and uses thereof
EP3096761A1 (en) * 2014-01-24 2016-11-30 Confluence Life Sciences, Inc. Substituted pyroolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases
WO2016105525A2 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Novel pyrimidines as egfr inhibitors and methods of treating disorders
AU2019223168B2 (en) * 2018-02-23 2024-09-12 The Regents Of The University Of Michigan EGFR dimer disruptors and use of the same

Also Published As

Publication number Publication date
BR112020017184A2 (pt) 2020-12-22
EP3755323A4 (en) 2021-11-24
US11999731B2 (en) 2024-06-04
MX2020008767A (es) 2021-01-08
KR102748047B1 (ko) 2024-12-27
AU2019223168A1 (en) 2020-09-10
EA202092000A1 (ru) 2020-12-09
CN111886009A (zh) 2020-11-03
EP3755323A1 (en) 2020-12-30
WO2019165358A1 (en) 2019-08-29
CA3091834A1 (en) 2019-08-29
US20220340572A1 (en) 2022-10-27
KR20200124709A (ko) 2020-11-03
US20200377503A1 (en) 2020-12-03
JP2024056735A (ja) 2024-04-23
JP2021514001A (ja) 2021-06-03
JP7497046B2 (ja) 2024-06-10
US11358965B2 (en) 2022-06-14

Similar Documents

Publication Publication Date Title
US11999731B2 (en) EGFR dimer disruptors and use of the same
TWI733679B (zh) Hpk1抑制劑及其使用方法
AU2021230372A1 (en) Inhibitors of EGFR, KRAS, BRAF, and other targets and use of the same
CN108602821B (zh) 1h-咪唑并[4,5-b]吡啶基bet溴结构域抑制剂
WO2018033815A1 (en) Pyridopyrimdinone cdk2/4/6 inhibitors
AU2021230553A1 (en) Inhibitors of EGFR, KRAS, BRAF, and other targets and use of the same
CA3068854A1 (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
CN111153899A (zh) 一种取代吡啶化合物、其制备方法和用途
EP3204359A1 (en) Tetrahydroisoquinoline derivatives
AU2007276788A1 (en) Compounds and compositions as hedgehog signaling pathway modulators
CA3177022A1 (en) Compounds and methods for yap/tead modulation and indications therefor
WO2024129634A1 (en) Rbm39 sulfonamide inhibitors
CA3233398A1 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
EA042609B1 (ru) Ингибиторы димеризации egfr и их использование
HK40034660A (en) Egfr dimer disruptors and use of the same
HK40057478B (en) Hpk1 inhibitors and methods of using same
EP4741375A1 (en) Sulfonylurea derivatives and their use for the treatment of cancer
WO2026099404A1 (en) Sulfonylurea derivatives and their use for the treatment of cancer
EP4729515A1 (en) New acylsulfonamide derivatives and their use for the treatment of cancer
HK1263053A1 (en) Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)